Bicocca Open Archive

Logo unimib boa
FALANGA, ANNA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.193
AS - Asia 6.526
EU - Europa 4.579
SA - Sud America 1.215
Continente sconosciuto - Info sul continente non disponibili 688
AF - Africa 192
OC - Oceania 10
Totale 25.403
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.085
SG - Singapore 2.744
HK - Hong Kong 1.364
IT - Italia 1.246
RU - Federazione Russa 1.002
CA - Canada 976
BR - Brasile 906
CN - Cina 836
VN - Vietnam 665
IE - Irlanda 558
SE - Svezia 527
DE - Germania 476
BD - Bangladesh 207
FR - Francia 206
IN - India 171
GB - Regno Unito 144
AR - Argentina 108
AT - Austria 85
ID - Indonesia 81
UA - Ucraina 81
MX - Messico 68
IQ - Iraq 67
ZA - Sudafrica 59
NL - Olanda 51
TR - Turchia 51
EC - Ecuador 45
FI - Finlandia 45
PH - Filippine 44
PK - Pakistan 42
CO - Colombia 41
JP - Giappone 40
ES - Italia 38
SA - Arabia Saudita 35
KR - Corea 31
VE - Venezuela 30
MA - Marocco 29
PL - Polonia 25
CL - Cile 22
UZ - Uzbekistan 22
PE - Perù 20
PY - Paraguay 19
RO - Romania 19
TN - Tunisia 17
ET - Etiopia 16
CR - Costa Rica 14
DZ - Algeria 14
JM - Giamaica 13
MY - Malesia 13
AE - Emirati Arabi Uniti 12
DK - Danimarca 12
JO - Giordania 12
KE - Kenya 12
NP - Nepal 12
UY - Uruguay 12
BO - Bolivia 11
CH - Svizzera 11
EG - Egitto 10
IL - Israele 10
OM - Oman 9
TH - Thailandia 9
AU - Australia 8
HN - Honduras 8
KZ - Kazakistan 8
PT - Portogallo 8
AL - Albania 7
CZ - Repubblica Ceca 7
GR - Grecia 7
LB - Libano 7
MU - Mauritius 7
PA - Panama 7
DO - Repubblica Dominicana 6
KG - Kirghizistan 5
KH - Cambogia 5
PS - Palestinian Territory 5
SV - El Salvador 5
BA - Bosnia-Erzegovina 4
GE - Georgia 4
GT - Guatemala 4
IR - Iran 4
SN - Senegal 4
BY - Bielorussia 3
GA - Gabon 3
LY - Libia 3
RS - Serbia 3
TT - Trinidad e Tobago 3
AM - Armenia 2
AO - Angola 2
AZ - Azerbaigian 2
BE - Belgio 2
BG - Bulgaria 2
CI - Costa d'Avorio 2
EE - Estonia 2
GP - Guadalupe 2
HU - Ungheria 2
LT - Lituania 2
ML - Mali 2
MM - Myanmar 2
NE - Niger 2
NZ - Nuova Zelanda 2
PR - Porto Rico 2
Totale 24.695
Salva come PNG Salva come JPEG
Città #
Singapore 1.402
Hong Kong 1.347
Ann Arbor 981
Ashburn 908
Fairfield 851
Toronto 799
San Jose 789
Dublin 553
Woodbridge 417
Milan 403
Wilmington 378
Houston 374
New York 369
Chandler 362
Frankfurt am Main 333
Dallas 326
Princeton 312
Cambridge 286
Seattle 269
Santa Clara 262
Chicago 259
Council Bluffs 225
Ho Chi Minh City 213
The Dalles 213
Hanoi 171
Beijing 166
Los Angeles 159
Jacksonville 145
Altamura 141
Lawrence 140
Lauterbourg 136
Boardman 114
Rome 113
Moscow 87
São Paulo 83
Ottawa 81
San Diego 80
Buffalo 61
Nuremberg 51
Vienna 48
Andover 46
Columbus 43
Shanghai 42
Jakarta 40
Orem 40
Phoenix 37
London 35
Falls Church 32
Helsinki 32
Hefei 31
Salt Lake City 31
Tokyo 31
Rio de Janeiro 30
Atlanta 29
Brooklyn 29
Baghdad 28
Figino 28
Seoul 28
Guangzhou 24
Nanjing 24
Redmond 24
Brasília 23
Montreal 23
Dearborn 22
Florence 22
Da Nang 21
Tashkent 21
Dong Ket 20
Warsaw 20
Charlotte 19
Johannesburg 19
New Delhi 19
Dhaka 18
Haiphong 18
Norwalk 18
Tampa 18
Cape Town 15
Chennai 15
Naples 15
San Francisco 15
Turin 15
Amsterdam 14
Ankara 14
Belo Horizonte 14
Campinas 14
Denver 14
Detroit 14
Hải Dương 14
Lahore 14
Lancaster 14
Quito 14
Addis Ababa 13
Delhi 13
Elk Grove Village 13
Guayaquil 13
Istanbul 13
Medellín 13
Newark 13
Paris 13
Poplar 13
Totale 15.724
Salva come PNG Salva come JPEG
Nome #
RECOMBINANT VERSUS HIGH-SENSITIVITY CONVENTIONAL THROMBOPLASTIN - A RANDOMIZED CLINICAL-STUDY IN PATIENTS ON ORAL ANTICOAGULATION 351
A microphysiological early metastatic niche on a chip reveals how heterotypic cell interactions and inhibition of integrin subunit β3 impact breast cancer cell extravasation 333
D-dimer testing, with gender-specific cutoff levels, is of value to assess the individual risk of venous thromboembolic recurrence in non-elderly patients of both genders: a post hoc analysis of the DULCIS study 329
Treatment of venous thromboembolism with tinzaparin in oncological patients 298
Fibrinolytic Proteins and Factor XIII as Predictors of Thrombotic and Hemorrhagic Complications in Hospitalized COVID-19 Patients 297
Thrombotic biomarkers for risk prediction of malignant disease recurrence in patients with early stage breast cancer 276
Long-term outcomes of patients with cerebral vein thrombosis: a multicenter study 273
FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor 267
Prevention of venous thromboembolism in patients with cancer: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET) 260
Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry 252
Tissue Plasminogen Activator Levels and Risk of Breast Cancer in a Case-Cohort Study on Italian Women: Results from the Moli-sani Study 246
Post-operative heparin reduces early venous thrombotic complications after orthotopic paediatric liver transplantation 246
Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2) 245
Thrombin generation predicts early recurrence in breast cancer patients 237
Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Two-year outcomes after the study closure 233
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update 227
Venous thromboembolism and cancer: Guidelines of the Italian Association of Medical Oncology (AIOM) 224
ISTH interim guidance on recognition and management of coagulopathy in COVID-19 218
The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH 216
Clozapine-induced anemia: A case-report 215
Activated prothrombin complex concentrate (FEIBA ® ) in acquired haemophilia A: a large multicentre Italian study – the FAIR Registry 214
Proceedings of the Second “International Conference on Thrombosis and Hemostasis Issues in Cancer”. September 19-21, 2003. Bergamo, Italy 213
Hemostatic biomarkers in occult cancer and cancer risk prediction 210
Anticoagulation resumption after intracranial hemorrhage in patients treated with VKA and DOACs 206
Thrombocytopenia and Mortality Risk in Patients With Atrial Fibrillation: An Analysis From the START Registry 204
DOACs and “newer” hemophilia therapies in COVID-19: Reply 202
Pathophysiology 1. Mechanisms of Thrombosis in Cancer Patients 199
D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study 199
Mechanisms and risk factors of thrombosis in cancer 196
Pathogenesis and management of the bleeding diathesis in acute promyelocytic leukaemia 195
Anticoagulation in thrombocytopenic patients with hematological malignancy: A multinational clinical vignette-based experiment 195
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review 195
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome 193
Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE 191
The predictive ability of bleeding risk stratification models in very old patients on vitamin K antagonist treatment for venous thromboembolism: Results of the prospective collaborative EPICA study 190
Grey zones on the use of new oral anticoagulants in atrial fibrillation. Expert opinion [Grey zones sull'uso dei nuovi anticoagulanti orali nella fibrillazione atriale. Opinioni degli esperti] 190
Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research 188
Fundamental Research in Oncology and Thrombosis 2 (FRONTLINE 2): A Follow-Up Survey 186
Combined use of antifibrinolytics and activated prothrombin complex concentrate (aPCC) is not related to thromboembolic events in patients with acquired haemophilia A: data from FAIR Registry 185
Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: A prospective multicentre study 183
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update Summary 183
Managing Anti-Platelet Therapy in Thrombocytopaenic Patients with Haematological Malignancy: A Multinational Clinical Vignette-Based Experiment 183
Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper 183
THE HYPERCOAGULABLE STATE IN CANCER-PATIENTS - EVIDENCE FOR IMPAIRED THROMBIN INHIBITIONS 182
Preliminary study to identify cancer patients at high risk of venous thrombosis following major surgery 181
Laboratory haemostasis monitoring in COVID-19 181
Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014 179
V. Plasmaferesi terapeutica 179
Pathogenesis and treatment of thrombohemorrhagic diathesis in acute promyelocytic leukemia 178
Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensus 177
Vitamin K-Dependent Procoagulant in Cancer Cells: A Potential Target for the Antimetastatic Effect of Warfarin? 173
Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine 173
Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 172
Low levels of ADAMTS-13 with high anti-ADAMTS-13 antibodies during remission of immune-mediated thrombotic thrombocytopenic purpura highly predict for disease relapse: A multi-institutional study 170
Association of plasma Protein C and CCL18 levels with neurodegenerative measures in Multiple Sclerosis patients 170
Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer-Associated Thrombosis: The Observational ROADMAP-CAT Study 168
Procoagulant activity of mouse transformed cells: Different expression in freshly isolated or cultured cells 168
Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera 167
The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia 166
Molecular biomarkers of thrombosis in myeloproliferative neoplasms 165
A Multidisciplinary Approach on the Perioperative Antithrombotic Management of Patients With Coronary Stents Undergoing Surgery: Surgery After Stenting 2 164
Comparison between different D-Dimer cutoff values to assess the individual risk of recurrent venous thromboembolism: Analysis of results obtained in the DULCIS study 164
Procoagulant mechanisms in tumour cells 163
The mechanisms of cancer-associated thrombosis 162
The effect of Vitamin E or selenium on the oxidant-antioxidant balance in rats 162
The prevention and management of asparaginase-related venous thromboembolism in adults: Guidance from the SSC on Hemostasis and Malignancy of the ISTH 159
Unbalanced plasma control of TxA2 and PGI2 synthesis in Vitamin E deficient rats 158
INEFFICACY OF INTRAVENOUS IMMUNOGLOBULIN IN PATIENTS WITH LOW-RISK THROMBOTIC THROMBOCYTOPENIC PURPURA/HEMOLYTIC-UREMIC SYNDROME 157
Type and dose of heparin in Covid-19: Reply 157
Venous thromboembolism in the hematologic malignancies 156
Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results 156
Anticoagulation in Italian patients with venous thromboembolism and thrombophilic alterations: findings from START2 register study 156
Thrombophilic status may predict prognosis in patients with metastatic BRAFV600-mutated melanoma who are receiving BRAF inhibitors 155
Edoxaban for the treatment of cancer-associated venous thromboembolism 154
Safety of vitamin K antagonist treatment for splanchnic vein thrombosis: a multicenter cohort study 154
Molecular basis for the relationship between thrombosis and cancer 152
Antithrombotic medication in cancer-associated thrombocytopenia: Current evidence and knowledge gaps 151
The Italian START-Register on anticoagulation with focus on atrial fibrillation 151
The management of acute venous thromboembolism in clinical practice - study rationale and protocol of the European PREFER in VTE Registry 151
Management of Cancer-associated Disseminated Intravascular Coagulation: guidance from the SSC of the ISTH 150
The effect of very-low-dose warfarin on markers of hypercoagulation in metastatic breast cancer: Results from a randomized trial 150
External validation of the DASH prediction rule: a retrospective cohort study 150
Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding 150
Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation 149
Hemostatic biomarkers in cancer progression 149
Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis 148
Evaluation of nucleated red blood cell count by Sysmex XE-2100 in patients with thalassaemia or sickle cell anaemia and in neonates 148
Microparticles in tumor progression 148
International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER) 147
Eradication of acquired hemophilia associated with indolent non-Hodgkin lymphoma by a disease specific treatment 147
Hypercoagulation screening as an innovative tool for risk assessment, early diagnosis and prognosis in cancer: The HYPERCAN study 146
Tissue Factor Expression on Platelet Surface during Preparation and Storage of Platelet Concentrates 146
La coagulopatia indotta da trauma 144
Tromboxane synthetase inhibition results in increased platelet sensivity to prostacyclin. Thrombosis and Haemostasis 143
Cancer and venous thromboembolism 143
Soluble stroma-related biomarkers of pancreatic cancer 142
Meeting Report EuroG20 Meeting on Cancer-Associated Thrombosis (CAT) Bergamo, Italy 7 April 2016 141
Proceedings of the Fifth International Conference on Thrombosis and Hemostasis Issues in Cancer, held in Stresa - Italy, April 23-25, 2010. Preface. 141
An unexpected case of recurrence of pulmonary embolism in a patient recovered from COVID19 in full regimen dose of direct oral anticoagulant drug 140
Phospholipid-dependent procoagulant activity is highly expressed by circulating microparticles in patients with Essential Thrombocythemia 139
Totale 18.718
Salva come PNG Salva come JPEG
Categoria #
all - tutte 99.127
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 99.127
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.234 0 0 178 95 64 76 93 102 69 98 110 349
2022/20232.027 370 568 182 133 95 404 7 90 95 17 41 25
2023/20241.469 26 52 20 18 227 403 259 44 243 20 5 152
2024/20254.320 303 731 200 166 354 74 289 96 414 610 329 754
2025/20269.937 655 606 828 948 924 524 1.317 586 772 676 1.100 1.001
2026/20271.572 326 673 573 0 0 0 0 0 0 0 0 0
Totale 25.403